| Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320) |
|---|
| 02/24/2009 | CA2322713C Process for the determination of ctp11 and for determining whether a tumor sample has metastatic potential |
| 02/24/2009 | CA2245497C Peptide immunogens for vaccination against and treatment of allergy |
| 02/24/2009 | CA2214633C Antibody purification by low-ph hydrophobic interaction chromatography |
| 02/24/2009 | CA2194236C Helicobacter proteins and vaccines |
| 02/24/2009 | CA2179029C Vertebrate embryonic pattern-inducing hedgehog-like proteins |
| 02/19/2009 | WO2009023816A1 Methods of making monoclonal antibodies using fusion- peptide epitope adoptive transfer (f-peat) technology |
| 02/19/2009 | WO2009023540A1 High affinity human antibodies to human nerve growth factor |
| 02/19/2009 | WO2009023457A1 Immunoglobulin cleavage fragments as disease indicators and compositions for detecting and binding such |
| 02/19/2009 | WO2009023265A1 Monoclonal antibody 175 targeting the egf receptor and derivatives and uses thereof |
| 02/19/2009 | WO2009023185A1 Cancer treatment using humanized antibodies that bind to ephb4 |
| 02/19/2009 | WO2009023184A2 Universal fibronectin type iii binding-domain libraries |
| 02/19/2009 | WO2009023047A2 Methods for the directed expansion of epitopes for use as antibody ligands |
| 02/19/2009 | WO2009023043A1 Immunoglobulins directed to bacterial viral and endogenous polypeptides |
| 02/19/2009 | WO2009022988A2 Vhz for diagnosis and treatment of cancer |
| 02/19/2009 | WO2009022632A1 Novel liver cancer marker |
| 02/19/2009 | WO2009022154A2 Peptide with multiple epitopes |
| 02/19/2009 | WO2009021754A2 Monospecific and multispecific antibodies and method of use |
| 02/19/2009 | WO2009021600A1 Detection of the human vascular endothelial growth factor |
| 02/19/2009 | WO2009021548A1 Expression of full length igg and secretion into the culture medium of prokaryotic cells |
| 02/19/2009 | WO2009021360A1 Gelsolin binding agent compositions and uses of same |
| 02/19/2009 | WO2009021295A2 Inhibition of alpha synuclein toxicity |
| 02/19/2009 | WO2008157356A3 Antibody formulations |
| 02/19/2009 | WO2008151200A3 Cancer related isoforms of components of transcription factor complexes as biomarkers and drug targets |
| 02/19/2009 | WO2008148546A3 Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a nir fluorescence label |
| 02/19/2009 | WO2008146165A3 Kit of parts for the treatment of cancer or infectious diseases |
| 02/19/2009 | WO2008143894A3 Phosphorylated rala |
| 02/19/2009 | WO2008127285A3 Target peptides for ovarian cancer immunotherapy |
| 02/19/2009 | WO2008060364A3 Humani zed antibody against amyloid beta |
| 02/19/2009 | WO2007129895A9 Deimmunized antagonistic anti-human cd40 monoclonal antibody from the ch5d12 antibody |
| 02/19/2009 | WO2007104511A8 Cancer vaccine |
| 02/19/2009 | WO2007084585A3 Non-human primate embryonic stem and germ cells: methods of use and methods of making same |
| 02/19/2009 | US20090048432 Anti-il-20 antibody and its use in treating il-20 associated inflammatory diseases |
| 02/19/2009 | US20090048324 Alternate morpheein forms of allosteric proteins as a target for the development of bioactive molecules |
| 02/19/2009 | US20090048209 Compositions comprising dc-sign blockers and methods of using dc-sign blockers for preventing or treating diseases of a mammal, including viral infections |
| 02/19/2009 | US20090048163 Nucleic acid and protein sequences of asporins |
| 02/19/2009 | US20090048150 Materials and Methods for the Detection of Nitrated Fibrinogen |
| 02/19/2009 | US20090048122 Stabilized polypeptide compositions |
| 02/19/2009 | US20090047741 Compositions and methods comprising a ligand of chemerin R |
| 02/19/2009 | US20090047737 Human LY6-Big Molecules and Methods of Use |
| 02/19/2009 | US20090047736 Human T1R2 nucleic acid sequences and polypeptides |
| 02/19/2009 | US20090047735 Antibodies Against Human G-Protein Chemokine Receptor (CCR5) HDGNR10 |
| 02/19/2009 | US20090047686 Methods for identifying and producing specific amino acid dependent antibodies and uses thereof |
| 02/19/2009 | US20090047668 Novel method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same |
| 02/19/2009 | US20090047660 Antibodies for oncogenic strains of HPV and methods of their use |
| 02/19/2009 | US20090047296 Antibodies conjugated to Auristatin analogs via a maleimidocaproyl lingages; for treating cancer, autoimmune diseases and infectious diseases |
| 02/19/2009 | US20090047292 Graft rejection suppressors |
| 02/19/2009 | US20090047291 Modulators of hepatocyte growth factor activator |
| 02/19/2009 | US20090047290 Monoclonal antibodies against beta3 integrins |
| 02/19/2009 | US20090047289 Osteopontin Specific Antibodies and Methods of Use Thereof |
| 02/19/2009 | US20090047287 Modulation of bone formation |
| 02/19/2009 | US20090047286 H2n3 influenza a viruses and methods of use |
| 02/19/2009 | US20090047285 Compositions and methods for diagnosing and treating cancer |
| 02/19/2009 | US20090047284 Methods and compositions for PDGF-C activation and inhibition |
| 02/19/2009 | US20090047283 Compounds and methods for treatment and diagnosis of chlamydial infection |
| 02/19/2009 | US20090047282 Prophylactic/Therapeutic Agent for Cancer |
| 02/19/2009 | US20090047280 Antibody inhibiting infection of papillomavirus |
| 02/19/2009 | US20090047277 Recombinant il-9 antibodies and uses thereof |
| 02/19/2009 | US20090047274 Diagnostic and therapeutic target cdc2l6 proteins for neurodegenerative diseases |
| 02/19/2009 | US20090047217 Polynucleotides Encoding Members of the Human B Lymphocyte Activation Antigen B7 Family and Polypeptides Encoded Thereby |
| 02/19/2009 | US20090047213 Cytotoxicity mediation of cells evidencing surface expression of CD59 |
| 02/19/2009 | US20090047211 Anti-mesothelin antibodies useful for immunological assays |
| 02/19/2009 | CA2722304A1 Immunoglobulins directed to bacterial, viral and endogeneous polypeptides |
| 02/19/2009 | CA2696360A1 Monoclonal antibody 175 targeting the egf receptor and derivatives and uses thereof |
| 02/19/2009 | CA2696164A1 Cancer treatment using humanized antibodies that bind to ephb4 |
| 02/19/2009 | CA2696047A1 A method for identifying, expanding, and removing adult stem cells and cancer stem cells |
| 02/19/2009 | CA2696011A1 Immunoglobulin cleavage fragments as disease indicators and compositions for detecting and binding such |
| 02/19/2009 | CA2695997A1 High affinity human antibodies to human nerve growth factor |
| 02/19/2009 | CA2695981A1 Vhz for diagnosis and treatment of cancer |
| 02/19/2009 | CA2695969A1 Regulators of mmp-9 and uses therof |
| 02/18/2009 | EP2025757A2 Polymeric immunoglobulin receptor-mediated gene transfer |
| 02/18/2009 | EP2025753A2 Phagemid for screening antibodies |
| 02/18/2009 | EP2025749A1 Humanized anti-human osteopontin antibody |
| 02/18/2009 | EP2025686A2 Alpha anticholine kinase monoclonal antibodies and their use in analytical techniques for the diagnosis of cancer and the preparation of medicinal products |
| 02/18/2009 | EP2025685A1 Monoclonal antibodies against BETA3 integrins |
| 02/18/2009 | EP2025682A2 Human endokine alpha |
| 02/18/2009 | EP2025657A2 Method for manufacturing carbon based shapes and their use as cell culture bearing and cultivation systems |
| 02/18/2009 | EP2025345A1 KIM-1 antagonists and use to modulate immune system |
| 02/18/2009 | EP2024748A2 Monoclonal anti-annexin a3 antibodies for the detection of prostate carcinoma |
| 02/18/2009 | EP2024396A2 Plad domain peptides with increased serum half life due to conjugation to domain antibodies |
| 02/18/2009 | EP2024395A2 Use of natriuretic peptides as diagnostic and prognostic indicators in vascular diseases |
| 02/18/2009 | EP2024394A2 Human binding molecules having killing activity against enterococci and staphylococcus aureus and uses thereof |
| 02/18/2009 | EP2024393A2 Neutralizing antibodies to influenza viruses |
| 02/18/2009 | EP2024392A2 Stabilized polypeptide compositions |
| 02/18/2009 | EP1679372B1 Novel plexin polypeptide, dna encoding the same and use thereof |
| 02/18/2009 | EP1618388B1 Proteomic analysis of biological fluids |
| 02/18/2009 | EP1587409A4 Diagnosis and monitoring of inflammation, ischemia and appendicitis |
| 02/18/2009 | EP1572094B1 Sodium channel alpha subunit variants |
| 02/18/2009 | EP1533320B1 HUMAN IgM ANTIBODY INDUCING APOPTOSIS IN HIV-INFECTED CELLS AND REMEDY FOR HIV-INFECTION |
| 02/18/2009 | EP1346034B1 VON WILLEBRAND FACTOR (vWF) CLEAVING PROTEASE POLYPEPTIDE, NUCLEIC ACID ENCODING THE POLYPEPTIDE AND USE OF POLYPEPTIDE |
| 02/18/2009 | EP1329503B1 Sphingolipid ceramide deacylase gene |
| 02/18/2009 | EP1140157B1 Streptococcus pneumoniae proteins and immunogenic fragments for vaccines |
| 02/18/2009 | EP1135467B1 Psca: prostate stem cell antigen and uses thereof |
| 02/18/2009 | EP1104405B1 Near infrared chemiluminescent acridinium compounds and uses thereof |
| 02/18/2009 | EP0969866B2 Immunotherapy of b-cell malignancies using anti-cd22 antibodies |
| 02/18/2009 | EP0941337B1 Synthesis and purification of hepatitis c virus-like particles |
| 02/18/2009 | EP0922761B1 Monoclonal antibody specific to anti-human fibrin monomer, process for producing the same, hybridomas, and immunoassay method |
| 02/18/2009 | CN101370832A Binding polypeptides and uses thereof |
| 02/18/2009 | CN101370831A Methods and compositions for treating allergic diseases |
| 02/18/2009 | CN101370830A Human monoclonal antibodies to CD70 |
| 02/18/2009 | CN101370829A Chimeric and humanised anti-human IL-13 antibodies |